Evinacumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Evinacumab
Accession Number
DB15354
Type
Biotech
Groups
Investigational
Description

Evinacumab is under investigation in clinical trial NCT03146416 (Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers).

Synonyms
Not Available
External IDs
REGN1500
Categories
UNII
T8B2ORP1DW
CAS number
1446419-85-7

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Evinacumab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Evinacumab.
AbrilumabThe risk or severity of adverse effects can be increased when Abrilumab is combined with Evinacumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Evinacumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Evinacumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Evinacumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Evinacumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evinacumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Evinacumab.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Evinacumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Evinacumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHypertriglyceridemias1
1CompletedTreatmentMetabolic Disorders1
2Active Not RecruitingTreatmentHigh Cholesterol1
2Active Not RecruitingTreatmentSevere Hypertriglyceridemia (sHTG)1
2CompletedTreatmentHomozygous Familial Hypercholesterolemia1
3CompletedTreatmentHomozygous Familial Hypercholesterolemia1
3Enrolling by InvitationTreatmentHomozygous Familial Hypercholesterolemia1
3Not Yet RecruitingTreatmentHomozygous Familial Hypercholesterolemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 09:19 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates